Genetic Variants in Vitamin D Pathway Genes and Risk of Pancreas Cancer; Results from a Population-Based Case-Control Study in Ontario, Canada

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Anderson, Laura N ^a   Cotterchio, Michelle ^b,c   Knight, Julia A ^a,b   Borgida, Ayelet ^a   Gallinger, Steven ^a,d   Cleary, Sean P ^a,d  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c CANCER CARE ONTARIO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM SENSING RECEPTOR; MEGALIN; RETINOID X RECEPTOR ALPHA; VITAMIN D BINDING PROTEIN; CHOLESTANETRIOL 26 MONOOXYGENASE; COLECALCIFEROL 24 HYDROXYLASE; CYP24A1 PROTEIN, HUMAN; CYP2R1 PROTEIN, HUMAN; STEROID MONOOXYGENASE; VITAMIN D;

ADULT; AGED; ARTICLE; CALCIUM SENSING RECEPTOR GENE; CANADA; CANCER RISK; CARCINOGENESIS; CASE CONTROL STUDY; CONTROLLED STUDY; CYP24A1 GENE; CYP2R1 GENE; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEGALIN GENE; PANCREAS CANCER; RETINOID X RECEPTOR ALPHA GENE; SINGLE NUCLEOTIDE POLYMORPHISM; VITAMIN D BINDING PROTEIN GENE; GENETIC PREDISPOSITION; GENETICS; METABOLISM; MIDDLE AGED; PANCREAS TUMOR; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CANADA; CASE-CONTROL STUDIES; CHOLESTANETRIOL 26-MONOOXYGENASE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN-2; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, CALCIUM-SENSING; RETINOID X RECEPTOR ALPHA; STEROID HYDROXYLASES; VITAMIN D; VITAMIN D-BINDING PROTEIN; VITAMIN D3 24-HYDROXYLASE; YOUNG ADULT;

EID: 84879496547     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0066768     Document Type: Article

References (33)

1. Maisonneuve P, Lowenfels AB, (2010) Epidemiology of pancreatic cancer: an update. Dig Dis 28: 645-656.
2. Zavoral M, Minarikova P, Zavada F, Salek C, Minarik M, (2011) Molecular biology of pancreatic cancer. World J Gastroenterol 17: 2897-2908.
3. Petersen GM, Amundadottir L, Fuchs CS, Kraft P, Stolzenberg-Solomon RZ, et al. (2010) A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nature Genetics 42: 224-228.
4. Wu C, Miao X, Huang L, Che X, Jiang G, et al. (2012) Genome-wide association study identifies five loci associated with susceptibility to pancreatic cancer in Chinese populations. Nature Genetics 44: 62-66.
5. Zhang X, Giovannucci E, (2011) Calcium, vitamin D and colorectal cancer chemoprevention. Best Pract Res Clin Gastroenterol 25: 485-494.
6. Shui IM, Mucci LA, Kraft P, Tamimi RM, Lindstrom S, et al. (2012) Vitamin D-related genetic variation, plasma vitamin D, and risk of lethal prostate cancer: a prospective nested case-control study. J Natl Cancer Inst 104: 690-699.
7. Chlebowski RT, (2011) Vitamin D and breast cancer: interpreting current evidence. Breast Cancer Res 13: 217.
8. Fleet JC, DeSmet M, Johnson R, Li Y, (2012) Vitamin D and cancer: a review of molecular mechanisms. Biochemical J 441: 61-76.
9. Schwartz GG, Eads D, Naczki C, Northrup S, Chen T, et al. (2008) 19-nor-1 alpha,25-dihydroxyvitamin D2 (paricalcitol) inhibits the proliferation of human pancreatic cancer cells in vitro and in vivo. Cancer Biol Ther 7: 430-436.
10. Schwartz GG, Eads D, Rao A, Cramer SD, Willingham MC, et al. (2004) Pancreatic cancer cells express 25-hydroxyvitamin D-1 alpha-hydroxylase and their proliferation is inhibited by the prohormone 25-hydroxyvitamin D3. Carcinogenesis 25: 1015-1026.
11. Persons KS, Eddy VJ, Chadid S, Deoliveira R, Saha AK, et al. (2010) Anti-growth effect of 1,25-dihydroxyvitamin D3-3-bromoacetate alone or in combination with 5-amino-imidazole-4-carboxamide-1-beta-4-ribofuranoside in pancreatic cancer cells. Anticancer Res 30: 1875-1880.
12. Stolzenberg-Solomon RZ, Jacobs EJ, Arslan AA, Qi D, Patel AV, et al. (2010) Circulating 25-hydroxyvitamin D and risk of pancreatic cancer: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol 172: 81-93.
13. Wolpin BM, Ng K, Bao Y, Kraft P, Stampfer MJ, et al. (2012) Plasma 25-hydroxyvitamin D and risk of pancreatic cancer. Cancer Epidemiol Biomarkers Prev 21: 82-91.
14. Skinner HG, Michaud DS, Giovannucci E, Willett WC, Colditz GA, et al. (2006) Vitamin D intake and the risk for pancreatic cancer in two cohort studies. Cancer Epidemiol Biomarkers Prev 15: 1688-1695.
15. Zablotska LB, Gong Z, Wang F, Holly EA, Bracci PM, (2011) Vitamin D, calcium, and retinol intake, and pancreatic cancer in a population-based case-control study in the San Francisco Bay area. Cancer Causes Control 22: 91-100.
16. Bao Y, Ng K, Wolpin BM, Michaud DS, Giovannucci E, et al. (2010) Predicted vitamin D status and pancreatic cancer risk in two prospective cohort studies. Br J Cancer 102: 1422-1427.
17. Giovannucci E, Liu Y, Rimm EB, Hollis BW, Fuchs CS, et al. (2006) Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J Natl Cancer Inst 98: 451-459.
18. Wang TJ, Zhang F, Richards JB, Kestenbaum B, van Meurs JB, et al. (2010) Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet 376: 180-188.
19. Ahn J, Yu K, Stolzenberg-Solomon R, Simon KC, McCullough ML, et al. (2010) Genome-wide association study of circulating vitamin D levels. Hum Mol Genet 19: 2739-2745.
20. Orton SM, Morris AP, Herrera BM, Ramagopalan SV, Lincoln MR, et al. (2008) Evidence for genetic regulation of vitamin D status in twins with multiple sclerosis. Am J Clin Nutr 88: 441-447.
21. Shea MK, Benjamin EJ, Dupuis J, Massaro JM, Jacques PF, et al. (2009) Genetic and non-genetic correlates of vitamins K and D. Eur J Clin Nutr. 63: 458-464.
22. Hunter D, De Lange M, Snieder H, MacGregor AJ, Swaminathan R, et al. (2001) Genetic contribution to bone metabolism, calcium excretion, and vitamin D and parathyroid hormone regulation. J Bone Miner Res 16: 371-378.
23. McCullough ML, Bostick RM, Mayo TL, (2009) Vitamin D gene pathway polymorphisms and risk of colorectal, breast, and prostate cancer. Annu Rev Nutr 29: 111-132.
24. Anderson LN, Cotterchio M, Gallinger S, (2009) Lifestyle, dietary, and medical history factors associated with pancreatic cancer risk in Ontario, Canada. Cancer Causes Control 20: 825-834.
25. Jang JH, Cotterchio M, Borgida A, Gallinger S, Cleary SP, (2012) Genetic variants in carcinogen-metabolizing enzymes, cigarette smoking and pancreatic cancer risk. Carcinogenesis 33: 818-827.
26. Gregory Warnes GG, Friedrich Leisch, Michael Man (2008) genetics: Population Genetics. R package version 1.3.4.
27. Sanchez GV, Weinstein SJ, Stolzenberg-Solomon RZ, (2012) Is dietary fat, vitamin D, or folate associated with pancreatic cancer? Mol Carcinog 51: 119-127.
28. Andreassen TK, (2006) The role of plasma-binding proteins in the cellular uptake of lipophilic vitamins and steroids. Horm Metab Res 38: 279-290.
29. Holt SK, Karyadi DM, Kwon EM, Stanford JL, Nelson PS, et al. (2008) Association of megalin genetic polymorphisms with prostate cancer risk and prognosis. Clin Cancer Res 14: 3823-3831.
30. Ding EL, Mehta S, Fawzi WW, Giovannucci EL, (2008) Interaction of estrogen therapy with calcium and vitamin D supplementation on colorectal cancer risk: reanalysis of Women's Health Initiative randomized trial. J Natl Cancer Inst 122: 1690-1694.
31. Dong LM, Ulrich CM, Hsu L, Duggan DJ, Benitez DS, et al. (2008) Genetic variation in calcium-sensing receptor and risk for colon cancer. Cancer Epidemiol Biomarkers Prev 17: 2755-2765.
32. Hibler EA, Hu C, Jurutka PW, Martinez ME, Jacobs ET, (2012) Polymorphic variation in the GC and CASR genes and associations with vitamin D metabolite concentration and metachronous colorectal neoplasia. Cancer Epidemiol Biomarkers Prev 21: 368-375.
33. Jacobs ET, Martinez ME, Campbell PT, Conti DV, Duggan D, et al. (2010) Genetic variation in the retinoid X receptor and calcium-sensing receptor and risk of colorectal cancer in the Colon Cancer Family Registry. Carcinogenesis 31: 1412-1416.